Oncothyreon Inc. (USA) (NASDAQ:ONTY) and Array BioPharma Inc. announced the initiation of a Phase 1b trial of ONT-380 (ARRY-380) in combination with Kadcyla (ado-trastuzumab emtansine or TDM-1) in patients with metastatic HER2+ breast cancer. Oncothyreon Inc (USA) (NASDAQ:ONTY) stock opened at $3.05 in last session, and closed at $3.29, while the day range of ONTY stock is $3.03 – $3.46. The stock showed a positive weekly performance of 14.24%.
Stifel Nicolaus began coverage on shares of Celladon Corp (NASDAQ:CLDN) in a report issued on Monday. The firm issued a buy rating and a $16.00 target price on the stock. Celladon Corp (NASDAQ:CLDN) stock opened at $10.18, in last session and closed at $10.79, by gaining 13.58%. The 52 week range of CLDN is $7.45 – $14.68. Company’s market capitalization is $190.71million.
Medivation, Inc. (NASDAQ:MDVN-Free Report) is a Zacks Rank #2 stock with an Earnings ESP of +36.36%. The Zacks Consensus Estimate for the fourth quarter stands at a loss of 11 cents. The company has a solid track record of delivering positive surprises with an average beat of 32.57% in the last four quarters. Medivation Inc (NASDAQ:MDVN) stock decreased -0.66% and finished the last session at $86.40. The EPS of the stock remained -1.02. Company’s market capitalization is $6.52billion.
Marina Biotech Inc (OTCMKTS:MRNA) announced entering into a binding term sheet with biotechnology investors led by Steven T. Newby. Marina Biotech, Inc. (OTCMKTS:MRNA) stock opened the session at $1.43, and closed the session at $1.71. The 52 week range of the MRNA stock remained $0.18 – $1.77 and the day range was $1.43 – $1.77.